HBW
VKTX icon

Hazlett, Burt & Watson’s Viking Therapeutics VKTX Stock Holding History

Hazlett, Burt & Watson’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed – – 953
2025
Q4 		$0 Sell
10
-70
-88% -$2.48K ﹤0.01% 957
2025
Q3 		$2K Sell
80
-10
-11% -$298 ﹤0.01% 822
2025
Q2 		$2K Buy
90
+20
+29% +$526 ﹤0.01% 739
2025
Q1 		$2K Hold
70
– – ﹤0.01% 740
2024
Q4 		$3K Hold
70
– – ﹤0.01% 684
2024
Q3 		$4K Hold
70
– – ﹤0.01% 630
2024
Q2 		$4K Hold
70
– – ﹤0.01% 617
2024
Q1 		$6K Buy
+70
New +$3.12K ﹤0.01% 568

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Hazlett, Burt & Watson's VKTX Position: Q1 2026 in Review

Hazlett, Burt & Watson sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 10 shares.

Hazlett, Burt & Watson first reported a position in VKTX in Q1 2024 and held it in 8 quarters. The position peaked at $6K in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Hazlett, Burt & Watson reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 10 Viking Therapeutics shares in Q1 2026.
  • Hazlett, Burt & Watson first reported a position in Viking Therapeutics in Q1 2024 and held it in 8 quarters.
  • Hazlett, Burt & Watson's Viking Therapeutics position peaked at $6K in Q1 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.